NCT00109590View on ClinicalTrials.gov

Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2009

Conditions
HIV Infections
Interventions
DRUG

Didanosine, enteric-coated

once daily

DRUG

Lopinavir/ritonavir

twice daily

DRUG

Nevirapine

single-dose at the onset of labor

DRUG

Zidovudine

twice daily

Trial Locations (7)

10220

Bhumibol Adulyadej Hosp. CRS, Saimai

10700

Siriraj Hospital Mahidol University CRS, Bangkok

20000

Chonburi Hosp. CRS, Chon Buri

22000

Prapokklao Hosp. CRS, Chanthaburi

50200

Chiang Mai University Pediatrics-Obstetrics CRS, Chiang Mai

56000

Phayao Provincial Hosp. CRS, Phayao

57000

Chiangrai Prachanukroh Hospital CRS, Chiangrai

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00109590 - Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth | Biotech Hunter | Biotech Hunter